# A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies

> **NCT04288141** · — · UNKNOWN · sponsor: **King's College London** · enrollment: 40 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **OTHER:** Acquisition of blood samples and tumour tissue samples (biopsies)

## Key facts

- **NCT ID:** NCT04288141
- **Lead sponsor:** King's College London
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-20
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04288141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04288141, "A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04288141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*